Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · IEX Real-Time Price · USD
+0.010 (0.85%)
At close: May 17, 2024, 4:00 PM
-0.030 (-2.52%)
Pre-market: May 20, 2024, 8:37 AM EDT

Aclaris Therapeutics Revenue

Aclaris Therapeutics had revenue of $31.12M in the twelve months ending March 31, 2024, with 0.95% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $2.40M, a -5.14% decrease year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
84.81M USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 202331.25M1.50M5.03%
Dec 31, 202229.75M22.99M340.05%
Dec 31, 20216.76M279.00K4.30%
Dec 31, 20206.48M2.26M53.35%
Dec 31, 20194.23M-1.92M-31.28%
Dec 31, 20186.15M4.47M265.48%
Dec 31, 20171.68M--
Dec 31, 20160--
Dec 31, 20150--
Dec 31, 20140--
Dec 31, 20130--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Spero Therapeutics 110.98M
Burning Rock Biotech 75.80M
Protalix BioTherapeutics 59.65M
Precision BioSciences 57.53M
Forian 20.49M
Gritstone bio 15.65M
Cue Biopharma 7.02M
Revenue Rankings